New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO ( oved by the FDA saidCharles Baum MD...)

New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO

oved by the FDA," said Charles Baum, MD, vice president of Pfizer Global Research and Development. "We are committed to investigating the role SUTENT may play in the treatment of advanced breast cancer through a comprehensive phase III program."

SUTENT (sunitinib malate) Phase III Trials in Breast Cancer

This phase III research program in advanced breast cancer will investigate sunitinib malate in multiple settings, including first, second and later lines, as both a single agent and in various combinations, including: combined with standard of care (SOC) chemotherapies versus SOC chemotherapies alone and combined with SOC chemotherapies versus other targeted therapies. The studies will evaluate sunitinib malate in patients with various types of advanced breast cancer including HER2 negative and positive, and previously treated advanced triple receptor negative (ER-, PR- and HER2-).

The phase II and III randomized, open-label studies that are currently enrolling include:

Phase III

-- SUN 1094: Sunitinib malate + paclitaxel versus bevacizumab + paclitaxel in first-line advanced breast cancer

-- SUN 1064: Sunitinib malate + docetaxel versus docetaxel alone in HER2- advanced breast cancer

-- SUN 1099: Sunitinib malate + capecitabine versus capecitabine alone in previously treated advanced breast cancer

-- SUN 1107: Single-agent sunitinib malate versus capecitabine in previously treated advanced breast cancer

Phase II

-- SUN 1077: Single-agent sunitinib malate versus chemotherapy in previously treated advanced triple receptor negative (ER-, PR-, and HER2-) breast cancer

-- SUN 1067: Sunitinib malate + trastuzumab versus trastuzumab + placebo in advanced breast cancer

About SUTENT(R) (sunitinib malate)

SUTENT is a multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) after disease progression on or intolera
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
5. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
8. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
9. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
10. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
11. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting

Post Your Comments:

( oved by the FDA saidCharles Baum MD...)New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO,Health